Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TAVR Leaflet Thickening Side-Effect Should Not Change Practice – EuroPCR

This article was originally published in The Gray Sheet

Executive Summary

New data presented at the EuroPCR conference in Paris suggest the valve leaflet thickening seen with St Jude Medical’s Portico transcatheter aortic valve is not a danger to patients.

You may also be interested in...



Warning Letter Roundup & Recap – 19 January 2021

No device-related warning letters were released by the US FDA the week of 19 January.

Start-Up Spotlight: CorWave Takes Inspiration From Nature To Tackle Heart Failure

Following a €2.5m award from the European Commission’s EIC Accelerator Program, Paris based CorWave has become the first EU company to obtain EIC fund investment. The company is developing a new pulsatile LVAD.

Immunocore Aims For $100m IPO After Immunotherapy Success

The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.

Topics

Related Companies

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel